Quick Answer
Rapport Therapeutics, Inc. reported Stockholders Equity of $484.65 million for fiscal year 2025.
Rapport Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $484.65M | +58.7% |
| 2024 | $305.43M | +1291.5% |
| 2023 | -$25.63M | -154.8% |
| 2022 | -$10.06M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $511.62M | +58.3% | +94.2% |
| June 30, 2025 | $263.51M | -21.8% | -7.8% |
| March 31, 2025 | $285.84M | +821.2% | -6.4% |
| December 31, 2024 | $305.43M | +1291.5% | -5.5% |
| September 30, 2024 | $323.11M | +2563.3% | -4.1% |
| June 30, 2024 | $336.89M | +3671.4% | +950.0% |
| March 31, 2024 | -$39.63M | -891.6% | -54.6% |
| December 31, 2023 | -$25.63M | -154.8% | -95.4% |
- Rapport Therapeutics, Inc. showed an increase of +58.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, Rapport Therapeutics, Inc.’s stockholders equity has grown by 4916.7% (from -$10.06 million to $484.65 million).
- The most recent figure is from Rapport Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: